Skip to content
Biodatica
Start free

Ono Pharmaceutical Co., Ltd.

Matsuyama, Ehime

OncologyPhase IIIListed · OPHLY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

3w agoTrial registeredJun 26, 2026Source filing (opens the source filing in a new tab)

Momentum

89no change

Momentum 89 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Oct 1, 2025

    Primary Central Nervous System Lymphoma (PCNSL) · COMPLETED · sponsor: Ono Pharmaceutical Co., Ltd. · A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

    ClinicalTrials.gov · NCT07198087 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    May 17, 2024

    Primary Central Nervous System Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Ono Pharmaceutical Co., Ltd. · Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL

    ClinicalTrials.gov · NCT06541665 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Oct 1, 2023

    Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · RECRUITING · sponsor: Ono Pharmaceutical Co., Ltd. · A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

    ClinicalTrials.gov · NCT06547528 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Nov 5, 2021

    Gastric Cancer · ACTIVE_NOT_RECRUITING · sponsor: Ono Pharmaceutical Co., Ltd. · A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

    ClinicalTrials.gov · NCT05144854 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Aug 6, 2021

    Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, EGFR Mutation-Related Tumors · COMPLETED · sponsor: Ono Pharmaceutical Co., Ltd. · Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

    ClinicalTrials.gov · NCT06525246 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Jan 13, 2021

    Metastatic Pancreatic Cancer · COMPLETED · sponsor: Ono Pharmaceutical Co., Ltd. · An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

    ClinicalTrials.gov · NCT06538207 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources